Cancer Genetics Inc (CGIX) - Medical Equipment - Deals and Alliances Profile

Cancer Genetics Inc (CGIX) - Medical Equipment - Deals and Alliances Profile


  • Products Id :- GDME259459D
  • |
  • Pages: 73
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Cancer Genetics Inc (CGI) is a pharmaceutical company that provides diagnostics products and services in oncology areas. The company offers products such as CGH microarrays, next-generation sequencing and DNA-FISH Probes. Its oncology tests and laboratory services offer critical genomic information to healthcare professionals, biopharma companies, and cancer centers. CGI provides clinical services such as expand DX, test menu, complete program, and summation report. The company offers a range of pharmacogenomics testing services for clinical oncologists, cancer centers, and research institutions, and for biotech and biopharma customers. It works in research collaboration with cancer centers to develop and validate proprietary tests. CGI is headquartered in Rutherford, New Jersey, the US.

Cancer Genetics Inc (CGIX)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Cancer Genetics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Cancer Genetics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Cancer Genetics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Cancer Genetics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9

Cancer Genetics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Cancer Genetics Inc, Medical Equipment, Deal Details 11

Asset Purchase 11

Cancer Genetics Acquires Assets of Response Genetics for USD14 Million 11

Partnerships 13

PierianDx Enters into Agreement with Cancer Genetics 13

Cancer Genetics Enters into Partnership with Mendel Health 14

Cancer Genetics Enters into Agreement with Lantern Pharma 15

Cancer Genetics Partners with ApoCell for ApoStream 16

Cancer Genetics Partners with H3 Biomedicine 17

Cancer Genetics Enters into Distribution Agreement with Sayre Therapeutics 18

Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 19

Cancer Genetics Italia Enters Into Distribution Agreement With Nikon Instruments 20

Merger 21

NovellusDx to Merge with Cancer Genetics 21

Equity Offering 23

Cancer Genetics Prices USD7 Million in Private Placement of Units 23

Cancer Genetics Raises USD3 Million in First Tranche of Private Placement of Shares 24

Cancer Genetics to Raise USD5.5 Million in Private Placement of Shares and Warrants 25

Cancer Genetics Raises USD5 Million in Private Placement of Shares and Warrants 26

Cancer Genetics Raises USD12 Million in Public Offering of Shares 27

Cancer Genetics Completes Public Offering Of Shares For USD 46 Million 29

Cancer Genetic Announces Public Offering Of Common Stock For Up To USD 50 Million 31

Cancer Genetics Completes Underwriters' Exercise Of Partial Over-Allotment Option For Public Offering Of Shares For USD 16 Million 32

Cancer Genetics Completes IPO For USD 7 Million 33

Debt Offering 35

Cancer Genetics Raises USD2.6 Million in Private Placement of 10% Notes Due 2019 35

Acquisition 36

ReproCELL Acquires BioServe Biotech from Cancer Genetics for USD1.9 Million 36

Cancer Genetics Inc-Key Competitors 37

Cancer Genetics Inc-Key Employees 38

Cancer Genetics Inc-Locations And Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Joint Venture 40

Recent Developments 41

Strategy And Business Planning 41

Sep 20, 2018: Cancer Genetics and NovellusDx agree to merge 41

Apr 03, 2017: Cancer Genetics and Mendel Announce Strategic Partnership Enabling Artificial Intelligence in Precision Medicine to Drive Personalized Treatment and Accelerate Clinical Trial Matching for Cancer Care 42

Financial Announcements 43

Aug 14, 2018: Cancer Genetics announces second quarter 2018 financial results 43

May 15, 2018: Cancer Genetics Reports First Quarter 2018 Financial Results and Provides Strategic Business Updates 45

Apr 02, 2018: Cancer Genetics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Strategic Business Updates 47

Nov 09, 2017: Cancer Genetics Reports Record Third Quarter 2017 Revenue and 134% Increase in Contracted Bookings from Major Biotech and Pharmaceutical Companies 49

Aug 14, 2017: Cancer Genetics Announces Second Quarter 2017 Financial Results, Accretive Acquisition and Capital Raise 51

May 11, 2017: Cancer Genetics Announces 15% Revenue Increase in First Quarter of 2017 over 2016 on Strong Organic Growth While Continuing on Path to Profitability 53

Mar 23, 2017: Cancer Genetics Announces Record Revenue for Fourth Quarter and Full-Year 2016 and Provides 2017 Business Update 55

Corporate Communications 57

Jun 12, 2018: Cancer Genetics Appoints Michael McCartney As Chief Commercial Officer 57

Feb 05, 2018: Cancer Genetics Announces Resignation Of Panna Sharma As Chief Executive Officer 58

Nov 27, 2017: Cancer Genetics Appoints Renowned Biotech Entrepreneur Dr. Thomas F. Widmann to its Board of Directors 59

Feb 22, 2017: Cancer Genetics to Receive USD 1.0 Million in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program 60

Legal and Regulatory 61

May 06, 2018: Kaskela Law: Shareholder Class Action Filed Against Cancer Genetics 61

Product News 62

Sep 20, 2018: Cancer Genetics offers Oncomine comprehensive assay to drive clinical trials 62

Dec 11, 2017: Cancer Genetics Advances Understanding of Immune Response and Measurement in Lymphomas by Combining PD-L1 Expression Analysis With RNA Analysis 63

Oct 30, 2017: Cancer Genetics a Leader in Personalized Medicine-Launches AntigenID, Solidifying CGI's Position as a Precision Oncology Leader in the Fast Growing, Rapidly-Evolving Field of Immuno-Oncology Therapy & Drug Development 64

Oct 12, 2017: Cancer Genetics to Host Panel Discussion on The Convergence of Artificial Intelligence and Healthcare-New Developments in Precision Medicine 65

Sep 20, 2017: Cancer Genetics Announces 25th Contract Win to Provide Testing & Diagnostic Services for Combination Immuno-Oncology Clinical Trial 66

Jun 02, 2017: Cancer Genetics to Present at the 7th Annual LD Micro Invitational 67

Mar 13, 2017: Cancer Genetics to Present at A Future Without Cancer Conference on Friday, March 17 68

Other Significant Developments 69

Oct 08, 2018: Cancer Genetics and Cellaria partner on precision medicine tools 69

Nov 29, 2017: Cancer Genetics Initiates Partnership to Reduce Alarmingly Increasing Cancer Mortality Rates in India 70

Apr 10, 2017: Cancer Genetics is Selected by eFFECTOR Therapeutics to Provide Biomarker Discovery and Development Services for Novel Oncology Drugs 71

Jan 06, 2017: Cancer Genetics Announces Consolidation and Cost Reduction in Administrative and Operational Support Functions 72

Appendix 73

Methodology 73

About GlobalData 73

Contact Us 73

Disclaimer 73

List of Figures

Cancer Genetics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Cancer Genetics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Cancer Genetics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Cancer Genetics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Cancer Genetics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Cancer Genetics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7

Cancer Genetics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Cancer Genetics Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

List of Tables

Cancer Genetics Inc, Medical Equipment, Key Facts, 2017 2

Cancer Genetics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Cancer Genetics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Cancer Genetics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Cancer Genetics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Cancer Genetics Inc, Deals By Market, 2012 to YTD 2018 9

Cancer Genetics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Cancer Genetics Acquires Assets of Response Genetics for USD14 Million 11

PierianDx Enters into Agreement with Cancer Genetics 13

Cancer Genetics Enters into Partnership with Mendel Health 14

Cancer Genetics Enters into Agreement with Lantern Pharma 15

Cancer Genetics Partners with ApoCell for ApoStream 16

Cancer Genetics Partners with H3 Biomedicine 17

Cancer Genetics Enters into Distribution Agreement with Sayre Therapeutics 18

Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 19

Cancer Genetics Italia Enters Into Distribution Agreement With Nikon Instruments 20

NovellusDx to Merge with Cancer Genetics 21

Cancer Genetics Prices USD7 Million in Private Placement of Units 23

Cancer Genetics Raises USD3 Million in First Tranche of Private Placement of Shares 24

Cancer Genetics to Raise USD5.5 Million in Private Placement of Shares and Warrants 25

Cancer Genetics Raises USD5 Million in Private Placement of Shares and Warrants 26

Cancer Genetics Raises USD12 Million in Public Offering of Shares 27

Cancer Genetics Completes Public Offering Of Shares For USD 46 Million 29

Cancer Genetic Announces Public Offering Of Common Stock For Up To USD 50 Million 31

Cancer Genetics Completes Underwriters' Exercise Of Partial Over-Allotment Option For Public Offering Of Shares For USD 16 Million 32

Cancer Genetics Completes IPO For USD 7 Million 33

Cancer Genetics Raises USD2.6 Million in Private Placement of 10% Notes Due 2019 35

ReproCELL Acquires BioServe Biotech from Cancer Genetics for USD1.9 Million 36

Cancer Genetics Inc, Key Competitors 37

Cancer Genetics Inc, Key Employees 38

Cancer Genetics Inc, Other Locations 39

Cancer Genetics Inc, Subsidiaries 39

Cancer Genetics Inc, Joint Venture 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Cancer Genetics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17810
Site License
USD 500 INR 35620
Corporate User License
USD 750 INR 53430

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com